肿瘤源性外泌体在口腔鳞状细胞癌中的研究进展

doi:10.13591/j.cnki.kqyx.2025.06.013

Abstract

Abstract:

Oral squamous cell carcinoma is a common malignant tumor of the head and neck. Early surgery can achieve good results, but most patients have cervical lymph node metastasis at the time of initial diagnosis. Although surgery combined with radiotherapy or chemotherapy can delay the progression of the disease, the overall prognosis is still not ideal. Especially in patients at stage Ⅲ / Ⅳ, the long-term survival rate has not improved. As a key microbubble in intercellular communication, exosomes contain a large number of biological molecules such as nucleic acids, proteins and lipids. Tumor-derived exosomes play a key role in regulating the tumor microenvironment. This article reviews the effects of tumor-derived exosomes on tumor proliferation, metastasis, immune regulation, diagnosis and treatment in oral squamous cell carcinoma, in order to provide new ideas for early diagnosis and treatment of oral cancer.

Key words: tumor-derived exosomes, oral squamous cell carcinoma, interaction, diagnosis, treatment, prognosis

CLC Number:

R782

ZHOU Xing’an, DELEHEI Bateer, WU Xu, MA Hongyu, XIA Fengjun, SHEN Tiebing, SHANG Duo. Research progress of tumor-derived exosomes in oral squamous cell carcinoma[J]. Stomatology, 2025, 45(6): 465-469.

References 38

[1]	Shang QH, Jiang YC, Wan ZX, et al. The clinical implication and translational research of OSCC differentiation[J]. Br J Cancer, 2024, 130(4): 660-670.
[2]	Vatsa PP, Jindal Y, Bhadwalkar J, et al. Role of epigenetics in OSCC: An understanding above genetics[J]. Med Oncol, 2023, 40(4): 122. doi: 10.1007/s12032-023-01992-0 pmid: 36941511
[3]	Krylova SV, Feng DR. The machinery of exosomes: Biogenesis, release, and uptake[J]. Int J Mol Sci, 2023, 24(2): 1337.
[4]	Sahu S, Routray S. Assessing the analytical efficacy of TEX in diagnosing oral cancer using a systematic review approach[J]. J Oral Pathol Med, 2021, 50(2): 123-128. doi: 10.1111/jop.13126 pmid: 33184963
[5]	Wan MH, Ning B, Spiegel S, et al. Tumor-derived exosomes (TDEs): How to avoid the sting in the tail[J]. Med Res Rev, 2020, 40(1): 385-412. doi: 10.1002/med.21623 pmid: 31318078
[6]	Mondal J, Pillarisetti S, Junnuthula V, et al. Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications[J]. J Control Release, 2023, 353: 1127-1149.
[7]	徐英娇, 王姗. 唾液外泌体在口腔鳞状细胞癌的研究进展[J]. 口腔医学, 2022, 42(7): 664-667, 672.
[8]	Boussadia Z, Zanetti C, Parolini I. Role of microenvironmental acidity and tumor exosomes in cancer immunomodulation[J]. Transl Cancer Res, 2020, 9(9): 5775-5786. doi: 10.21037/tcr.2020.03.69 pmid: 35117938
[9]	Kalele K, Nyahatkar S, Mirgh D, et al. Exosomes: A cutting-edge theranostics tool for oral cancer[J]. ACS Appl Bio Mater, 2024, 7(3): 1400-1415.
[10]	Li L, Li C, Wang SX, et al. Exosomes derived from hypoxic oral squamous cell carcinoma cells deliver miR-21 to normoxic cells to elicit a prometastatic phenotype[J]. Cancer Res, 2016, 76(7): 1770-1780. doi: 10.1158/0008-5472.CAN-15-1625 pmid: 26992424
[11]	Song Q, Yu H, Cheng YD, et al. Bladder cancer-derived exosomal KRT6B promotes invasion and metastasis by inducing EMT and regulating the immune microenvironment[J]. J Transl Med, 2022, 20(1): 308. doi: 10.1186/s12967-022-03508-2 pmid: 35794606
[12]	Li YY, Tao YW, Gao S, et al. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p[J]. EBio Medicine, 2018, 36: 209-220.
[13]	Guo HJ, Jiang WD, Huang SH, et al. Serum exosome-derived biomarkers for the early detection of oral squamous cell carcinoma[J]. Mol Cell Biochem, 2021, 476(12): 4435-4447. doi: 10.1007/s11010-021-04254-7 pmid: 34468926
[14]	Zhou JW, Tang ZW, Gao SY, et al. Tumor-associated macrophages: Recent insights and therapies[J]. Front Oncol, 2020, 10: 188. doi: 10.3389/fonc.2020.00188 pmid: 32161718
[15]	Pradhan R, Paul S, Acharya SS, et al. Nano formulated Resveratrol inhibits PD-L1 in oral cancer cells by deregulating the association between tumor associated macrophages and cancer associated fibroblasts through IL-6/JAK2/STAT3 signaling axis[J]. J Nutr Biochem, 2024, 125: 109568.
[16]	Pang X, Wang SS, Zhang M, et al. Correction to: OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway[J]. Cancer Immunol Immunother, 2022, 71(2): 505-506.
[17]	Cai JH, Qiao B, Gao N, et al. Oral squamous cell carcinoma-derived exosomes promote M2 subtype macrophage polarization mediated by exosome-enclosed miR-29a-3p[J]. Am J Physiol Cell Physiol, 2019, 316(5): C731-C740.
[18]	Paskeh MDA, Entezari M, Mirzaei S, et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling[J]. J Hematol Oncol, 2022, 15(1): 83.
[19]	Xu ZJ, Chen Y, Ma L, et al. Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment[J]. Mol Ther, 2022, 30(10): 3133-3154. doi: 10.1016/j.ymthe.2022.01.046 pmid: 35405312
[20]	Alipoor SD, Mortaz E, Varahram M, et al. The potential biomarkers and immunological effects of tumor-derived exosomes in lung cancer[J]. Front Immunol, 2018, 9: 819. doi: 10.3389/fimmu.2018.00819 pmid: 29720982
[21]	Naseri M, Bozorgmehr M, Zöller M, et al. Tumor-derived exosomes: The next generation of promising cell-free vaccines in cancer immunotherapy[J]. Oncoimmunology, 2020, 9(1): 1779991.
[22]	Theodoraki MN, Yerneni SS, Hoffmann TK, et al. Clinical significance of PD-L1⁺ exosomes in plasma of head and neck cancer patients[J]. Clin Cancer Res, 2018, 24(4): 896-905.
[23]	Zhu XQ, Qin X, Wang XN, et al. Oral cancer cell-derived exosomes modulate natural killer cell activity by regulating the receptors on these cells[J]. Int J Mol Med, 2020, 46(6): 2115-2125.
[24]	Chen YY, Li ZY, Liang JF, et al. CircRNA has_circ_0069313 induced OSCC immunity escape by miR-325-3p-Foxp3 axes in both OSCC cells and Treg cells[J]. Aging, 2022, 14(10): 4376-4389.
[25]	Qin X, Guo HY, Wang XN, et al. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5[J]. Genome Biol, 2019, 20(1): 12. doi: 10.1186/s13059-018-1604-0 pmid: 30642385
[26]	Zheng Y, Song A, Zhou Y, et al. Identification of extracellular vesicles-transported miRNAs in Erlotinib-resistant head and neck squamous cell carcinoma[J]. J Cell Commun Signal, 2020, 14(4): 389-402.
[27]	Gao F, Han JJ, Wang Y, et al. Circ_0109291 promotes cisplatin resistance of oral squamous cell carcinoma by sponging miR-188-3p to increase ABCB1 expression[J]. Cancer Biother Radiopharm, 2022, 37(4): 233-245.
[28]	Yuan Y, Wang ZY, Chen MQ, et al. Macrophage-derived exosomal miR-31-5p promotes oral squamous cell carcinoma tumourigenesis through the large tumor suppressor 2-mediated hippo signalling pathway[J]. J Biomed Nanotechnol, 2021, 17(5): 822-837. doi: 10.1166/jbn.2021.3066 pmid: 34082869
[29]	Faur CI, Roman RC, Jurj A, et al. Salivary exosomal microRNA-486-5p and microRNA-10b-5p in oral and oropharyngeal squamous cell carcinoma[J]. Medicina, 2022, 58(10): 1478.
[30]	Lin XJ, Wu WZ, Ying YK, et al. MicroRNA-31: A pivotal oncogenic factor in oral squamous cell carcinoma[J]. Cell Death Discov, 2022, 8(1): 140. doi: 10.1038/s41420-022-00948-z pmid: 35351880
[31]	Li CP, Zhou Y, Liu JJ, et al. Potential markers from serum-purified exosomes for detecting oral squamous cell carcinoma metastasis[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(10): 1668-1681.
[32]	Lu J, Liu QH, Wang F, et al. Exosomal miR-9 inhibits angiogenesis by targeting MDK and regulating PDK/AKT pathway in nasopharyngeal carcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1): 147. doi: 10.1186/s13046-018-0814-3 pmid: 30001734
[33]	Li M, Yin SY, Xu AN, et al. Synergistic phototherapy-molecular targeted therapy combined with tumor exosome nanoparticles for oral squamous cell carcinoma treatment[J]. Pharmaceutics, 2023, 16(1): 33.
[34]	Xie C, Du LY, Guo FY, et al. Exosomes derived from microRNA-101-3p-overexpressing human bone marrow mesenchymal stem cells suppress oral cancer cell proliferation, invasion, and migration[J]. Mol Cell Biochem, 2019, 458(1/2): 11-26.
[35]	Kamerkar S, Leng CR, Burenkova O, et al. Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity[J]. Sci Adv, 2022, 8(7): eabj7002.
[36]	Liang YJ, Duan L, Lu JP, et al. Engineering exosomes for targeted drug delivery[J]. Theranostics, 2021, 11(7): 3183-3195. doi: 10.7150/thno.52570 pmid: 33537081
[37]	Yong TY, Zhang XQ, Bie NN, et al. Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy[J]. Nat Commun, 2019, 10(1): 3838. doi: 10.1038/s41467-019-11718-4 pmid: 31444335
[38]	Solomon MC, Chandrashekar C, Kulkarni S, et al. Exosomes: Mediators of cellular communication in potentially malignant oral lesions and head and neck cancers[J]. F1000 Res, 2023, 12: 58.

Research progress of tumor-derived exosomes in oral squamous cell carcinoma

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 38

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	TAO Nannan, LI Wenlei, CHEN Xing, SONG Weijian, ZHOU Hongyan. A clinical analysis of three methods for repairing deciduous molars [J]. Stomatology, 2025, 45(5): 367-370.
[2]	HUANG Shuhui, ZHU Zhu, WANG Yunyi, XU Yuyue, LI Jing, YU Gang, ZHANG Feng. Progress in the application of artificial intelligence in the diagnosis and treatment of maxillofacial fractures [J]. Stomatology, 2025, 45(5): 386-393.
[3]	LI Jinpeng, JIANG Yinhua. Progress of research on the correlation between adenoid hypertrophy and malocclusion in children [J]. Stomatology, 2025, 45(4): 311-316.
[4]	CHEN Yue, SUN Xueqian, CHEN Minmin. Research progress of lncRNA UCA1 in oral squamous cell carcinoma [J]. Stomatology, 2025, 45(4): 317-320.
[5]	CHEN Xu, LI Lu, WANG Xiaoqian, WANG Tianyao, XU Yan. Progress of diagnosis and treatment decisions in stage Ⅲ/Ⅳ periodontitis [J]. Stomatology, 2025, 45(1): 13-17.
[6]	BAO Jiaqi, WANG Zhongxiu, FENG Yimiao, LEI Lihong, CHEN Lili. Management of periodontal hard tissue related complications in orthodontic treatment [J]. Stomatology, 2025, 45(1): 37-44.
[7]	ZHOU Yue, TANG Zhenxing, LI Yu. Molar anchorage loss and its influencing factors in orthodontic cases with premolar extraction [J]. Stomatology, 2025, 45(1): 64-68.
[8]	WANG Pan, LYU Jiong, ZHU Huiyong. Research progress of reversing treatment resistance in head and neck squamous cell carcinoma by targeting lipid metabolism [J]. Stomatology, 2024, 44(9): 705-709.
[9]	ZHAO Tingting, HE Hong. Clinical pathway for the treatment of malocclusion in children with OSA [J]. Stomatology, 2024, 44(8): 561-564.
[10]	PU Panjun, ZHAO Huaxiang, MOU Qingnan, LIANG Rong, HOU Yuxia. Sequential treatment of maxillary retraction in cleft lip and palate [J]. Stomatology, 2024, 44(8): 570-575.
[11]	LIU Anqi, XIA Lunguo. Digital early intervention and multi-disciplinary treatment with malocclusion [J]. Stomatology, 2024, 44(8): 576-580.
[12]	XIONG Ke, ZHANG Hao, HU Tuqiang. Experimental study on emodin regulating the proliferation of oral squamous cell carcinoma cells through autophagy [J]. Stomatology, 2024, 44(8): 602-608.
[13]	YI Jie, DING Yujie, SHAN Yufei, GU Jiaqi, SUN Zhida. Neutrophil extracellular traps regulating the development and prognosis of oral squamous cell carcinomas [J]. Stomatology, 2024, 44(7): 500-517.
[14]	LIU Hongyan, ZHENG Siyi, WEI Xi. New advances in vital pulp therapy for the treatment of irreversible pulpitis: From biological basic to clinical perspective [J]. Stomatology, 2024, 44(6): 401-407.
[15]	SONG Ye, REN Yinting, ZHANG Yihan, HAN Jingying. The effect of different tooth extraction patterns on Bolton index and occlusal relationship of skeletal Class Ⅱ malocclusion [J]. Stomatology, 2024, 44(5): 334-337.